Q. Cai, J. Lin, L. Wei, L. Zhang, L. Wang, Y. Zhan, J. Zeng, W. Xu, A. Shen, Z. Hong and J. Peng, “ Hedyotis Diffusa Willd Inhibits Colorectal Cancer Growth in Vivo via Inhibition of STAT3 Signaling Pathway,” International Journal of Molecular Science, Vol. 13, No. 5, 2012, pp. 6117-6128. doi:10.3390/ijms13056117

has been cited by the following article:

• TITLE: Traditional Chinese Medicinal Syndromes and Treatment in Colorectal Cancer

  AUTHORS: Shan Deng, Bing Hu, Hong-Mei An

  KEYWORDS: Colorectal Cancer; Syndrome Differentiation; Traditional Chinese Medicinal Treatment; Anti-Cancer Herb

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.6A, November 30, 2012

  ABSTRACT: Colorectal cancer remains the third most common malignancy worldwide. According to the principles of Traditional Chinese Medicine (TCM), colorectal cancer is related to spleen-deficiency, damp-heat, and toxicity accumulation. Traditional Chinese medicine has been confirmed to effectively reduce toxic side effects and enhance curative effects of chemotherapy, palliate clinical syndrome, prevent recurrence and metastasis, improve quality of life and immune function, and prolong survival time in colorectal cancer. However, TCM theoretical and syndrome differentiation study has lagged far behind due to progression of therapy model in colorectal cancer. As a type of drug treatment, there are some common biological basis between chemotherapy, targeted therapy and anti-cancer herb therapy in colorectal cancer, such as apoptosis, cell senescence and autophagy. There are growing needs to explore the effect mechanism and compatibility of anti-cancer herbs, to further enhance the efficacy of TCM treatment in colorectal cancer.